These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19307678)

  • 1. Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
    Witjes CD; Verhoef C; Verheul HM; Eskens FA
    Neth J Med; 2009 Mar; 67(3):86-90. PubMed ID: 19307678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
    Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy of hepatocellular carcinoma: are we making progress?
    Roxburgh P; Evans TR
    Adv Ther; 2008 Nov; 25(11):1089-104. PubMed ID: 18972075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
    Lord R; Suddle A; Ross PJ
    Int J Clin Pract; 2011 Feb; 65(2):182-8. PubMed ID: 21235699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
    Gish RG; Abou-Alfa GK; Tong MJ
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):2 p preceding 4-15. PubMed ID: 21598749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    Peck-Radosavljevic M; Greten TF; Lammer J; Rosmorduc O; Sangro B; Santoro A; Bolondi L
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):391-8. PubMed ID: 19940784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS
    Clin Cancer Res; 2010 Jan; 16(2):390-7. PubMed ID: 20068087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting for treatment of advanced hepatocellular carcinoma.
    Song IH
    Korean J Hepatol; 2009 Sep; 15(3):299-308. PubMed ID: 19783879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L; Santoro A
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
    Zhu AX
    Oncologist; 2006; 11(7):790-800. PubMed ID: 16880238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the treatment of hepatocellular carcinoma.
    Singal AG; Marrero JA
    Curr Opin Gastroenterol; 2010 May; 26(3):189-95. PubMed ID: 20224395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapeutic strategies in the management of hepatocellular carcinoma.
    Lee IJ; Seong J
    Oncology; 2011; 81 Suppl 1():123-33. PubMed ID: 22212946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel advancements in the management of hepatocellular carcinoma in 2008.
    Llovet JM; Bruix J
    J Hepatol; 2008; 48 Suppl 1():S20-37. PubMed ID: 18304676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of hepatocellular carcinoma and molecular therapies.
    Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
    Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA; Galle PR
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.